Groundbreaking: FDA Reviews MDMA Therapy For PTSD, Accepts New Drug Application



Three Key Takeaways:

FDA Nods to MDMA Therapy Application: The FDA has accepted Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, marking a significant step in recognizing psychedelic therapies’ medical potential.
A Milestone in Psychedelic Research: This development, supported by MAPS’ extensive research, signifies a historical move toward potentially approving MDMA-assisted therapy, which could lead to more psychedelic treatments being accepted.
Safety and Efficacy Still Reviewed: Despite the FDA’s priority review, MDMA-assisted therapy’s safety and effectiveness for PTSD are still under scrutiny. The continued investigation reflects a careful approach toward incorporating psychedelic therapies into mental health care.

The U.S. Food and Drug Administration (FDA) has recently accepted a New Drug Application (NDA) from Lykos Therapeutics for the use of MDMA-assisted therapy in treating Post-Traumatic Stress Disorder (PTSD). This decision marks a significant milestone in the journey toward potentially integrating psychedelic-assisted therapies into mainstream medical practice. Lykos Therapeutics, which evolved …

Full story available on


Leave a Reply

Your email address will not be published. Required fields are marked *